AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amneal Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$19.36+0.18 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $6.35B
- P/E (TTM)
- 39.5
- Dividend yield
- –
Amneal Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $6.18B | $164.85M |
| Enterprise Value | $8.63B | $87.06M |
| PE Ratio | 39.51 | 19.63 |
| PS Ratio | 1.98 | 3.60 |
| PB Ratio | 187.22 | 2.03 |
| P/FCF Ratio | 48.36 | 17.44 |
| P/OCF Ratio | 30.79 | 13.32 |
Enterprise value
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.77 | 2.43 |
| EV / EBITDA | 19.00 | 14.69 |
| EV / EBIT | 19.00 | 18.47 |
| EV / FCF | 67.47 | 20.97 |
Income (trailing twelve months)
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $3.12B | $57.94M |
| Gross Profit | $1.23B | $90.47M |
| Operating Income | $453.92M | -$21.44M |
| Pretax Income | $201.18M | -$14.45M |
| Net Income | $157.36M | -$22.46M |
| EBITDA | $453.92M | -$16.91M |
| EPS (Diluted) | $0.49 | -$0.83 |
Margins
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 39.3% | 52.3% |
| Operating Margin | 14.6% | -44.5% |
| Pretax Margin | 6.45% | -13.0% |
| Profit Margin | 5.05% | -39.2% |
| EBITDA Margin | 14.6% | -31.3% |
| FCF Margin | 4.10% | -8.85% |
Returns
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | 4.37% | -41.0% |
| Return on Invested Capital (ROIC) | 20.3% | -32.0% |
| Return on Capital Employed (ROCE) | 15.7% | -37.8% |
Growth
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 9.28% | 6.01% |
| Net Income Growth (YoY) | 4562.6% | -37.7% |
| EPS Growth (YoY) | 4800.0% | -29.2% |
| FCF Growth (YoY) | -54.8% | 2.34% |
| Revenue Growth (3Y CAGR) | 10.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 8.66% | 6.42% |
| EPS Growth (5Y CAGR) | -18.5% | 3.77% |
Balance sheet
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $127.64M | $62.42M |
| Total Debt | $2.57B | $120.13M |
| Net Cash (Debt) | -$2.44B | $15.68M |
| Net Cash Per Share | -$7.65 | $0.66 |
| Equity (Book Value) | $33.02M | $48.79M |
| Book Value Per Share | $0.10 | $1.36 |
| Tangible Book Value | -$1.15B | $23.06M |
| Working Capital | $1.06B | $75.77M |
Financial position
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.20 | 3.30 |
| Quick Ratio | 0.14 | 2.39 |
| Debt / Equity | 77.83 | 0.51 |
| Debt / EBITDA | 5.66 | 3.35 |
| Debt / FCF | 20.11 | 5.05 |
| Net Debt / EBITDA | 5.38 | 2.22 |
Cash flow (trailing twelve months)
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $200.78M | -$12.35M |
| Capital Expenditures | -$72.94M | -$1.06M |
| Free Cash Flow | $127.84M | -$20.28M |
| FCF Per Share | $0.40 | -$0.42 |
Efficiency
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.87 | 0.38 |
| Inventory Turnover | 2.94 | 2.67 |
| Revenue Per Employee | $366.77K | $398.96K |
| Profits Per Employee | $18.51K | -$703.34K |
| Employee Count | 8,500 | 74 |
Dividends and yields
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 2.55% | -22.7% |
| FCF Yield | 2.07% | -9.07% |
Shares
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 319,354,000 | 58,179,650 |
| Shares Change (YoY) | 3.48% | 11.1% |
| Float | 125,531,000 | 49,173,100 |
| Shares Held by Insiders | 60.7% | 11.6% |
| Shares Held by Institutions | 52.7% | 59.4% |
Taxes
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$14.14M | $91.50K |
| Effective Tax Rate | -7.03% | 20.6% |
Scores
| Measure | Amneal Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $1.07 | $17.36 |
| Graham Upside | -94.5% | -43.6% |
| Altman Z-Score | 2.40 | -0.24 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Amneal Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.